Monty Krieger

Education

  • PhD, 1976, California Institute of Technology
  • BS, 1971, Chemistry, Tulane University

Research Summary

We use genetic, biochemical, physiologic, chemical, cellular and molecular biological methods to study cell surface receptor structure and function. We focus on lipoprotein receptors — in particular, the High Density Lipoprotein (HDL) receptor called Scavenger Receptor, Class B, Type I (SR-BI). Our analyses have provided insight into basic biological processes, contributed to our understanding of atherosclerosis and coronary heart disease (CHD) and have uncovered an unexpected connection between cholesterol and mammalian female infertility.

Awards 

  • Tulane University School of Science and Engineering Outstanding Alumnus Award, 2010
  • National Academy of Sciences, Member, 2009
  • Outstanding Achievement Award for Contributions to Atherosclerosis Research, International Atherosclerosis Society, 2009
  • Margaret MacVicar Faculty Fellow, 1993-2003
Omer H. Yilmaz

Education

  • PhD, 2008, University of Michigan; MD, 2008, University of Michigan Medical School
  • BS, 1999, Biochemistry and Physics, University of Michigan

Research Summary

The adult intestine is maintained by stem cells that require a cellular neighborhood, or niche, consisting in part of Paneth cells. Our laboratory will investigate the molecular mechanisms of how intestinal stem cells and their Paneth cell niche respond to diverse diets to coordinate intestinal regeneration with organismal physiology and its impact on the formation and growth of intestinal cancers.  By better understanding how intestinal stem cells adapt to diverse diets, we hope to identify and develop new strategies that prevent and reduce the growth of cancers involving the intestinal tract that includes the small intestine, colon, and rectum.

Awards

  • AAAS Martin and Rose Wachtel Cancer Research Award, 2018
  • Pew-Stewart Trust Scholar, 2016-2020
  • Sidney Kimmel Scholar, 2016-2020
  • V Foundation Scholar, 2014-2017
  • Harold M. Weintraub Award, 2007
David C. Page

Education

  • MD, 1984, Harvard Medical School
  • BS, 1978, Chemistry, Swarthmore College

Research Summary

We seek to understand the genetic differences between males and females — both within and beyond the reproductive tract. We study the medical ramifications of these differences in a broad context, through comparative biological, evolutionary, developmental and clinically focused analyses. Our three main veins of research relate to sex differences in health and disease, sex chromosome genomics, and germ cell origins and development.

Awards

  • American Academy of Arts and Sciences, Fellow, 2012
  • March of Dimes, Developmental Biology, 2011
  • National Academy of Medicine, Member, 2008
  • National Academy of Sciences, Member, 2005
  • Howard Hughes Medical Institute, HHMI Investigator, 1990
  • MacArthur Foundation, MacArthur Fellowship, 1986
Richard A. Young

Education

  • PhD, 1979, Yale University
  • BS, 1975, Biological Sciences, Indiana University

Research Summary

We use experimental and computational technologies to determine how signaling pathways, transcription factors, chromatin regulators and small RNAs regulate gene expression in healthy and diseased cells. Our interests range from the basic molecular mechanisms behind gene control to drug development for cancer and other diseases caused by gene misregulation.

Awards

  • National Academy of Medicine, Member, 2019
  • National Academy of Sciences, Member, 2012
Eliezer Calo

Education

  • PhD, 2011, MIT
  • BS, 2006, Chemistry, University of Puerto Rico-Río Piedras

Research Summary

We focus on the molecular entities controlling and coordinating RNA metabolism — that is, the compendium of processes that involve RNA, including protein synthesis, processing, modifications, export, translation and degradation. Our goal is to understand how different aspects of RNA metabolism are controlled to generate structure and function during development, as well as how mutations in components of the RNA metabolic program lead to congenital disorders and cancer.

David Housman

Education

  • PhD, 1971, Brandeis University
  • BS, 1966, Biology, Brandeis University

Research Summary

We use genetic approaches to identify the molecular basis of human disease pathology. More specifically, we develop strategies to combat three major disease areas: cancer, trinucleotide repeat disorders like Huntington’s disease, and cardiovascular disease.

Awards

  • National Academy of Medicine, Member, 1997
  • National Academy of Sciences, Member, 1994
Leonard P. Guarente

Education

  • PhD, 1978, Harvard University
  • SB, 1974, Biology, MIT

Research Summary

We combine comprehensive bioinformatics analyses with functional analyses of pathways and genes to study aging in humans and mice. We apply these approaches to identify the major pathways and genes involved in the aging of certain brain regions. We are also studying muscular dystrophy and muscle loss with aging. Ultimately, our findings may guide studies in other organs and lead to a systemic understanding of mammalian aging.

Awards

  • Miami Winter Symposium, Feodor Lynen Award, 2012
  • University of Toronto, Charles H. Best Lectureship and Award, 2011
  • Dart/NYU Biotechnology, Achievement Award, 2009
  • French Academie des Sciences, Elected, 2009
  • American Academy of Arts and Sciences, Fellow, 2004
Revealing an imperfect actor in plant biotechnology

Whitehead Institute researchers detect the chemical mistakes of a common herbicide-resistance enzyme, then successfully re-engineer it for enhanced precision.

Nicole Davis | Whitehead Institute
November 29, 2017

A research team led by MIT’s Whitehead Institute for Biomedical Research has harnessed metabolomic technologies to unravel the molecular activities of a key protein that enables plants to withstand a common herbicide.

Their findings reveal how the protein — a kind of catalyst or enzyme first isolated in bacteria and introduced into plants such as corn and soybeans in the 1990s — can sometimes act imprecisely, and how it can be successfully re-engineered to be more precise. The new study, which appears online in the journal Nature Plants, raises the standards for bioengineering in the 21st century.

“Our work underscores a critical aspect of bioengineering that we are now becoming technically able to address,” says senior author Jing-Ke Weng, a member of the Whitehead Institute and an assistant professor of biology at MIT. “We know that enzymes can behave indiscriminately. Now, we have the scientific capabilities to detect their molecular side effects, and we can leverage those insights to design smarter enzymes with enhanced specificity.”

Plants provide an extraordinary model for scientists to study how metabolism changes over time. Because they cannot escape from predators or search for new food sources when supplies run low, plants must often grapple with an array of environmental insults using what is readily available — their own internal biochemistry.

“Although they appear to be stationary, plants have rapidly evolving metabolic systems,” Weng explains. “Now, we can gain an unprecedented view of these changes because of cutting-edge techniques like metabolomics, allowing us to analyze metabolites and other biochemicals on a broad scale.”

Key players in this evolutionary process, and a major focus of research in Weng’s laboratory, are enzymes. Traditionally, these naturally occurring catalysts have been viewed as mini-machines, taking the proper starting material (or substrate) and flawlessly converting it to the correct product. But Weng and other scientists now recognize that they make mistakes, often by latching on to an unintended substrate.

“This concept, known as enzyme promiscuity, has a variety of implications, both in enzyme evolution and more broadly, in human disease,” Weng says.

It also has implications for bioengineering, as Bastien Christ, a postdoctoral fellow in Weng’s laboratory, and his colleagues recently discovered.

Christ, then a graduate student in Stefan Hörtensteiner’s lab at the University of Zurich in Switzerland, was studying a particular strain of the flowering plant Arabidopsis thaliana as part of a separate project when he made a puzzling observation. He found that two biochemical compounds were present at unusually high levels in the plant’s leaves.

Strangely, these compounds (called acetyl-aminoadipate and acetyl-tryptophan) weren’t present in any of the normal, so-called wild type plants. As he and his colleagues searched for an explanation, they narrowed in on the source: an enzyme, called BAR, that was engineered into the plants as a kind of chemical beacon, enabling scientists to more readily study them.

But BAR is more than just a tool for scientists. It is also one of the most commonly deployed traits in genetically modified crops such as soybeans, corn, and cotton, enabling them to withstand a widely-used herbicide (known as phosphinothricin or glufosinate).

For decades, scientists have known that BAR, originally isolated from bacteria, can render the herbicide inactive by tacking on a short string of chemicals, made of two carbons and one oxygen (also called an acetyl group). As the researchers describe in their Nature Plants paper, BAR has a promiscuous side, and can work on other substrates, too, such as the amino acids tryptophan and aminoadipate (a lysine derivative).

That explains why they can detect the unintended products (acetyl-tryptophan and acetyl-aminoadipate) in crops genetically engineered to carry BAR, such as soybeans and canola.

Their research included detailed studies of the BAR protein, including crystal structures of the protein bound to its substrates. This provided them with a blueprint for how to strategically modify BAR to make it less promiscuous, and favor only the herbicide as a substrate and not the amino acids. Christ and his colleagues created several versions that lack the non-specific activity of the original BAR protein.

“These are natural catalysts, so when we borrow them from an organism and put them into another, they may not necessarily be perfect for our purposes,” Christ says. “Gathering this kind of fundamental knowledge about how enzymes work and how their structure influences function can teach us how to select the best tools for bioengineering.”

There are other important lessons, too. When the BAR trait was first evaluated by the U.S. Food and Drug Administration (FDA) in 1995 for use in canola, and in subsequent years for other crops, metabolomics was largely non-existent as a technology for biomedical research. Therefore, it could not be applied toward the characterization of genetically engineered plants and foods, as part of their regulatory review. Nevertheless, acetyl-aminoadipate and acetyl-tryptophan, which are normally present in humans, have been reviewed by the FDA and are safe for human and animal consumption.

Weng and his colleagues believe their study makes a strong case for considering metabolomics analyses as part of the review process for future genetically engineered crops.

“This is a cautionary tale,” Weng says.

The work was supported by the Swiss National Science Foundation, the EU-funded Plant Fellows program, the Pew Scholar Program in the Biomedical Sciences, and the Searle Scholars Program.

Stefani Spranger

Education

  • PhD, 2011, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • MSc, Biology, 2008, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • BSc, Biology, 2005, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich

Research Summary

We examine the interaction between cancer and immune cells. Using tumor mouse models designed to mimic tumor progression in humans, we investigate the co-evolution of the anti-tumor immune response and cancer. Understanding the interplay between tumor cells and immune cells will help develop and improve effective cancer immunotherapies.

Awards

  • Forbeck Fellow, 2015
Jianzhu Chen

Education

  • PhD, 1990, Stanford University
  • BS, 1982, Biology, Wuhan University

Research Summary 

We seek to understand the immune system and its application in cancer immunotherapy and vaccine development. We study the molecular and cellular mechanisms behind immunological and disease processes, leveraging the vast array of genomic data, humanized mice and clinical samples.

Awards

  • American Association for the Advancement of Science, Fellow, 2012